Survey of treatment recommendations for elderly patients with glioblastoma

• M. A. Vaz Salgado ^[1] ; J. Torres ^[1] ; J. Esteban ^[1] ; J. A. Gutiérrez ^[2] ; L. Ley ^[2] ; A. Carrato ^[1]
  1. [1] Medical Oncology Department, Ramón y Cajal Hospital, Carretera de Colmenar Viejo Km 9.1, 28034 Madrid, Spain
  2. [2] Neurosurgery Department, Ramón y Cajal Hospital, Carretera de Colmenar Viejo Km 9.1, 28034 Madrid, Spain
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 8, 2020, págs. 1329-1334
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • ntroduction Glioblastoma, which is the most commonly diagnosed primary CNS neoplasm, is more frequent in individuals aged 65 years or more. Our purpose is to identify how glioblastoma diagnosed in elderly population is treated by Spanish oncologists.

    Material and Methods A survey was emailed to all members of Spanish Group for Neuro-oncology Research (GEINO).

    Results Twenty-six neuro-oncologists from 26 hospitals completed the survey. The answers were different depending on the age, performance status, and MGMT methylation status. Patients between 65 and 70 years of age are mainly treated with Stupp treatment. For patients between ages of 70 and 80 years, 46.2% made recommendations for Perry regimen, for both methylated and non-methylated patients. For patients older than 80 years, monotherapy treatment is considered more frequently. In cases of non-MGMT promoter methylation, systemic therapy with temozolomide is still recommended in many hospitals.

    Conclusion Our research demonstrates there is no uniform approach to the management of elderly patients with glioblastoma among academic neuro-oncologists.